Candel Therapeutics Inc [NASDAQ: CADL] closed the trading session at $6.75.
The stocks have a year to date performance of 359.18 percent and weekly performance of 31.32 percent. The stock has been moved at -7.41 percent over the last six months. The stock has performed 57.34 percent around the most recent 30 days and changed -7.28 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 2.42M shares, CADL reached to a volume of 18606225 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Candel Therapeutics Inc [CADL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CADL shares is $11.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CADL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Candel Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 02, 2022. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on November 19, 2021, representing the official price target for Candel Therapeutics Inc stock. Previously, the target price had yet another raise to $9, while UBS analysts kept a Buy rating on CADL stock.
CADL stock trade performance evaluation
Candel Therapeutics Inc [CADL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.32. With this latest performance, CADL shares gained by 57.34% in over the last four-week period, additionally sinking by -7.41% over the last 6 months – not to mention a rise of 467.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CADL stock in for the last two-week period is set at 56.74, with the RSI for the last a single of trading hit 56.52, and the three-weeks RSI is set at 56.00 for Candel Therapeutics Inc [CADL]. The present Moving Average for the last 50 days of trading for this stock 5.35, while it was recorded at 6.79 for the last single week of trading, and 5.95 for the last 200 days.
Candel Therapeutics Inc [CADL]: An insightful look at the core fundamentals
Candel Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.18 and a Current Ratio set at 1.18.
Candel Therapeutics Inc [CADL]: Institutional Ownership
There are presently around $22.53%, or 32.37%% of CADL stock, in the hands of institutional investors. The top three institutional holders of CADL stocks are: NORTHPOND VENTURES, LLC with ownership of 1.94 million shares, which is approximately 6.628%. BLACKROCK INC., holding 0.82 million shares of the stock with an approximate value of $$5.1 million in CADL stocks shares; and BLACKROCK INC., currently with $$5.08 million in CADL stock with ownership which is approximately 2.8035%.
